These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Federico L; Pamuklar Z; Smyth SS; Morris AJ Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016 [TBL] [Abstract][Full Text] [Related]
11. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977 [TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of boronic acid based inhibitors of autotaxin. Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182 [TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699 [TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389 [TBL] [Abstract][Full Text] [Related]
15. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816 [TBL] [Abstract][Full Text] [Related]
16. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Xu X; Yang G; Zhang H; Prestwich GD Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):140-6. PubMed ID: 19682598 [TBL] [Abstract][Full Text] [Related]
17. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485 [TBL] [Abstract][Full Text] [Related]
18. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709 [TBL] [Abstract][Full Text] [Related]
19. Development of an activity-based probe for autotaxin. Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725 [TBL] [Abstract][Full Text] [Related]